Pharmacologic effect of Generic Zovirax
Generic Zovirax is active against Herpes simplex 1 and 2 types, the Varicella zoster virus, the Epstein-Barr virus and cytomegaloviruses. Thymidine kinase virus-infected cells through a series of consecutive reactions actively converts acyclovir into mono-, di- and triphosphate acyclovir. The latter interacts with the viral DNA polymerase and is embedded in DNA, which is synthesized for new viruses. Thus, “defective” viral DNA is formed, which leads to suppression of replication of new generations of viruses.
Description of dosage form
Tablets: blue, flat, in the form of a shield (irregular polygonal shape) tablets; On the one hand, the inscription “ZOVIRAX” is pushed out on the other side – a triangle. On the surface of the tablet, minor inclusions may be visible.
Powder for solution for injection: caked mass (porous cake) or lyophilized powder of white or almost white color. The preparation is hygroscopic.
Eye ointment: soft, homogeneous, white or almost white, translucent oily mass with a weak characteristic odor, which does not contain grains, lumps and foreign particles.
Clinical Pharmacology
In patients with severe immunodeficiency, prolonged or repeated courses of therapy with acyclovir can lead to the emergence of resistant strains, and therefore further treatment with acyclovir may not be effective. Most of the isolated strains with reduced sensitivity to acyclovir showed a relatively low content of viral thymidine kinase, a breakdown in the structure of viral thymidine kinase or DNA polymerase. The effect of acyclovir on HSV strains in vitro can also lead to the formation of less sensitive strains. There was no correlation between the sensitivity of the HSV strains to acyclovir in vitro and the clinical efficacy of the drug.
It was shown that the administration of Generic Zovirax in high doses reduces the frequency of occurrence and delays the development of CMV infection. If after the infusion therapy Acyclovir (Zovirax) in a high dose is treated with Zovirax for oral administration at a high dose for 6 months, then the mortality and frequency of viremia develop.